Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped up before the market opened on Friday . The stock had previously closed at $6.71, but opened at $7.46. Telix Pharmaceuticals shares last traded at $7.8170, with a volume of 117,335 shares trading hands.

Analyst Ratings Changes

Several brokerages have commented on TLX. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Wall Street Zen cut shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

The company’s 50-day moving average is $7.51 and its 200 day moving average is $9.25.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its earnings results on Thursday, February 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $413.40 million for the quarter, compared to analyst estimates of $421.50 million. As a group, equities analysts predict that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current fiscal year.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of TLX. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Telix Pharmaceuticals in the second quarter worth $297,000. Pier Capital LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth about $3,037,000. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth about $975,000. Jane Street Group LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $564,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.